{
    "2021-04-27": [
        [
            {
                "time": "2021-04-27",
                "original_text": "Novartis Generics Face 'Challenging Quarter,' But Gene Therapy Shines",
                "features": {
                    "keywords": [
                        "Generics",
                        "Challenging Quarter",
                        "Gene Therapy"
                    ],
                    "sentiment_score": 0.3,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-05-03",
                "original_text": "Eli Lily Abandons IL-23 Psoriasis Program, Instead Will Focus On Ulcerative Colitis, Crohn's Disease Indications",
                "features": {
                    "keywords": [
                        "IL-23",
                        "Psoriasis",
                        "Ulcerative Colitis",
                        "Crohn's Disease"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-03-18",
                "original_text": "ANI Pharmaceuticals, Inc. -- Moody's assigns first-time B2 CFR to ANI Pharmaceuticals; outlook stable",
                "features": {
                    "keywords": [
                        "Moody's",
                        "B2 CFR",
                        "outlook stable"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals",
                        "finance"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-04-29",
                "original_text": "Novartis (NVS) Q1 2021 Earnings Call Transcript",
                "features": {
                    "keywords": [
                        "Q1",
                        "Earnings",
                        "Call Transcript"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-04-22",
                "original_text": "Novartis (NVS) Q1 Earnings & Sales Miss Estimates on COVID-19 Woes",
                "features": {
                    "keywords": [
                        "Q1",
                        "Earnings",
                        "Sales Miss",
                        "COVID-19"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2021-04-23",
                "original_text": "Why Novartis Missed Wall Street Q1 Estimates",
                "features": {
                    "keywords": [
                        "Missed",
                        "Wall Street",
                        "Q1 Estimates"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2021-04-24",
                "original_text": "Novartis Earnings, Sales Slightly Miss Q1 Views",
                "features": {
                    "keywords": [
                        "Earnings",
                        "Sales",
                        "Slightly Miss",
                        "Q1 Views"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2021-04-25",
                "original_text": "Novartis Earnings, Sales Slightly Miss First-Quarter Views",
                "features": {
                    "keywords": [
                        "Earnings",
                        "Sales",
                        "Slightly Miss",
                        "First-Quarter Views"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2021-04-26",
                "original_text": "Italy judge sends Bayer, Novartis to trial in drugs fraud probe: sources",
                "features": {
                    "keywords": [
                        "Italy",
                        "judge",
                        "Bayer",
                        "Novartis",
                        "trial",
                        "drugs fraud"
                    ],
                    "sentiment_score": -0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "legal",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2021-04-27",
                "original_text": "Italy judge sends Bayer, Novartis to trial in drugs fraud probe - sources",
                "features": {
                    "keywords": [
                        "Italy",
                        "judge",
                        "Bayer",
                        "Novartis",
                        "trial",
                        "drugs fraud"
                    ],
                    "sentiment_score": -0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "legal",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2021-04-28",
                "original_text": "Novartis Q1 Earnings Take A Hit Amid COVID-19 Impact",
                "features": {
                    "keywords": [
                        "Q1",
                        "Earnings",
                        "Hit",
                        "COVID-19"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2021-04-29",
                "original_text": "Novartis key growth drivers and launches continue momentum in Q1, maintaining confidence in growth. Group guidance for FY 2021 confirmed.",
                "features": {
                    "keywords": [
                        "key growth drivers",
                        "launches",
                        "momentum",
                        "confidence",
                        "FY 2021"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-04-30",
                "original_text": "Novartis warns of pandemic delay in cancer diagnoses",
                "features": {
                    "keywords": [
                        "pandemic",
                        "delay",
                        "cancer diagnoses"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}